Stephen Abo, DO
Hematology & Oncology · Newark, NJNPI 1891717708
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (57.8%), food and beverage and education — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Novartis at 58.4% of the total. Reporting peaked in 2024 at $1,508 and has fallen 57.1% since, to $646 in 2025. That places this record below the midpoint for hematology & oncology clinicians in NJ, where the typical reported total is $2,686.
Across 72 payments — averaging $39.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- AstraZeneca$381
- Astellas Pharma US Inc$200
- Johnson & Johnson$160
- Incyte Corporation$117
- Sanofi$93
- plus $224 from 10 others
What the payments were for
- Food & beverage$77728%
- Education$41215%
- Other$1,63158%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 19 | $1,646 |
| AstraZeneca | 25 | $381 |
| Astellas Pharma US Inc | 2 | $200 |
| Johnson & Johnson | 5 | $160 |
| Incyte Corporation | 2 | $117 |
| Sanofi | 5 | $93 |
| Amgen | 3 | $54 |
| Mirati Therapeutics, Inc. | 2 | $31 |
| Lilly USA, LLC | 2 | $29 |
| Pharmacosmos Therapeutics Inc. | 1 | $19 |
| Taiho Oncology, Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Octapharma USA, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Pfizer | 1 | $14 |
| Gilead | 1 | $12 |
How this compares
$2,820 in reported general payments places this provider in the 50th percentile of 362 hematology & oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 39 | $653,046 |
| ImbruvicaIbrutinib | 43 | $578,347 |
| CalquenceAcalabrutinib Maleate | 30 | $454,792 |
| XtandiEnzalutamide | 28 | $402,066 |
| SprycelDasatinib | 14 | $283,522 |
| RevlimidLenalidomide | 13 | $232,834 |
| KeytrudaPembrolizumab | 17 | $224,629 |
| JakafiRuxolitinib Phosphate | 13 | $215,335 |
| TagrissoOsimertinib Mesylate | 12 | $206,969 |
| KisqaliRibociclib Succinate | 12 | $204,106 |
| EliquisApixaban | 170 | $143,661 |
| BrukinsaZanubrutinib | 12 | $89,763 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 11 | $72,487 |
| XareltoRivaroxaban | 61 | $62,845 |
| Abiraterone Acetate | 21 | $12,238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $14 | $796,707209 claims |
| AstraZenecaCalquence, Tagrisso | $381 | $661,76042 claims |
| Astellas Pharma US IncXtandi | $200 | $402,06628 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $14 | $283,52214 claims |
| NovartisKisqali, Sandostatin Lar Depot | $1,646 | $276,59323 claims |
| Incyte CorporationJakafi | $117 | $215,33513 claims |
| Johnson & JohnsonXarelto | $160 | $62,84561 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 362 hematology & oncology providers in New Jersey.
Other hematology & oncology in Newark
- Alice CohenNewark$21K
- Robert SpiegelWestfield$864K
- Amit PatelJersey City$770K
- Joshua StraussSpringfield$739K
- Charles FarberMorristown$609K
- Michael ScolaMorristown$506K
- Eshan PatelSomerville$420K
- Arturo Loaiza-BonillaPennington$406K
- Ashish ShahSpringfield$394K
- Carl HenningsonManasquan$349K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.